八种生物类似药上市后长达18年真实世界安全性数据综述
该研究基于同一上市许可持有人(MAH)八种生物类似药的定期安全性更新报告(PSUR)及监管评估报告,汇总截至2023年1月31日的上市后累积暴露与安全性经验,暴露时长可达首款生物类似药上市后18年;分析认为每种产品的总体获益-风险特征仍为有利,且与各自参照生物药一致。
要点
- 八种生物类似药上市后累积安全性数据支持其总体获益-风险特征与参照生物药一致。
- 长达18年真实世界安全性经验为生物类似性概念提供了有力支持。
核心结论
- 八种生物类似药上市后长达18年的真实世界安全性数据表明,其总体获益-风险特征仍为有利,且与各自参照生物药一致。
研究设计与样本
- 基于同一MAH八种生物类似药的PSUR及相应监管机构PSUR评估报告,汇总截至2023年1月31日的上市后累积暴露与安全性经验。
- 暴露以患者治疗日(PTD)计算,利妥昔单抗以患者剂量数(PD)表示。
主要发现
- 对八种生物类似药PSUR累积安全性数据的关键分析认为,每种产品的总体获益-风险特征仍为有利,且与各自参照生物药一致。
临床怎么用
- 临床可依据该长期真实世界安全性数据,对生物类似药与参照生物药的临床获益和安全性保持信心。
局限性
- 数据来自单一MAH的八种生物类似药,结论外推至其他生物类似药需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Biosimilars are additional treatment options that are approved based on robust analytical and clinical comparisons with their reference biologic. At the time of initial approval, the full safety profile of a biosimilar is inferred from the reference biologic. Nonetheless, there are still lingering concerns related to the long-term safety of biosimilars. Therefore, we reviewed the post-approval pharmacovigilance data for eight marketed biosimilars from one Marketing Authorization Holder (MAH) to summarize their safety experience in a real-world setting for up to 18 years since their first biosimilar launch. METHODS: Post-approval cumulative patient exposure and safety experience for eight Sandoz biosimilars [adalimumab (Hyrimoz®), epoetin alfa (Binocrit®), etanercept (Erelzi®), filgrastim (Zarzio®), infliximab (Zessly®), pegfilgrastim (Ziextenzo®), rituximab (Rixathon®), and somatropin (Omnitrope®)] was summarized based on the available pharmacovigilance data from Periodic Safety Update Reports (PSURs) and the corresponding health authority-authored PSUR assessment reports, where available, as of 31 January 2023. Exposure to all biosimilars was calculated in patient treatment days (PTD) except for rituximab, which was expressed in number of patient doses (PD). RESULTS: The combined post-approval cumulative exposure to seven out of the eight marketed Sandoz biosimilars was more than 1.3 billion PTD and for rituximab more than 1.8 million PD. Overall, a critical analysis of the cumulative safety data of all eight Sandoz biosimilar PSURs concluded that the overall benefit-risk profile of each remains favorable and is consistent with the respective reference biologics. CONCLUSIONS: This is one of the largest reviews of post-approval biosimilar pharmacovigilance data to date by one MAH. The real-world experience of all eight marketed Sandoz biosimilars for up to 18 years demonstrates that Sandoz biosimilars can be used as safely as their respective reference biologics. Therefore, patients and healthcare providers can be confident in the clinical benefit and safety of Sandoz biosimilars. It is reasonable to believe that similar conclusions about safety may be reached for other biosimilars developed and approved to the high standards as are already in place by major health authorities such as the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). The long-term safety of biosimilars demonstrated here provides strong support for the concept of biosimilarity.
引用
- Sagi S, Anjaneya P, Kalsekar S, et al. Long-Term Real-World Post-approval Safety Data of Multiple Biosimilars from One Marketing-Authorization Holder After More than 18 Years Since Their First Biosimilar Launch. Drug Saf. 2023. PMID: 37902937. doi:10.1007/s40264-023-01371-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。